Key result
Menopausal hormone therapy and aging determine CV risk in peri- and postmenopausal women, requiring personalized prevention.
Why the study?
Cardiovascular disease awareness and risk in middle-aged women remain underestimated, prompting a review of cardiovascular risk realization in peri- and postmenopausal women.
What are the determinants of cardiovascular and cardiometabolic risks in peri- and postmenopausal women, and how does menopausal hormone therapy influence them?
What are the determinants of cardiovascular and cardiometabolic risks in peri- and postmenopausal women, and how does menopausal hormone therapy influence them?
Highlights the underestimation of cardiovascular risk in middle-aged women and calls for personalized, pathogenetically substantiated preventive strategies during peri- and postmenopause.
Answers are grounded in this paper and cite their sources.
May inform CV risk evaluation in middle-aged women; leaves open prospective validation of MHT personalization.
According to WHO, cardiometabolic disorders have remained the leading cause of death in the world for 20 years. Heart diseases account for 16% of deaths worldwide today, reaching 47% in Russia. Unfortunately, awareness of CVD as a leading cause of death remains insufficient among both women and physicians. The risk of CVD in middle-aged women remains underestimated and certainly requires timely interdisciplinary attention. The aim of the study was to conduct a literature review of databases in the context of studying the problem of cardiovascular risk realization in peri and postmenopausal women. Research methods . An analysis of evidence published in 2015-2025 in the Cochrane Library, PubMed, ELibrary, Science Direct, Scopus, Web of Science, Google Scholar electronic libraries was conducted using the keywords cardiovascular diseases, cardiovascular risk, peri and postmenopause, menopausal hormone therapy. Results of the study . The review presents the main determinants of the implementation of cardiometabolic and cardiovascular risks in women in peri and postmenopause both in terms of aging and in terms of the influence of menopausal hormone therapy. Conclusion . The presented data convincingly indicate that in order to prevent the implementation of cardiovascular risk in women in peri and postmenopause, it is necessary to create a personalized pathogenetically substantiated strategy of therapeutic and preventive measures based on the concept of preventive medicine.
No takes yet. Share an insight, caveat, or question.
Minyailo et al. (2025) conducted a review in Cardiovascular risk in peri- and postmenopausal women. Menopausal hormone therapy was evaluated. Menopausal hormone therapy and aging are key determinants of cardiovascular risk in peri- and postmenopausal women, necessitating personalized preventive strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: